$3.04
0.227.8%
最終更新: Oct 22, 5:02 PM
$3.00
0.186.38%
Benzinga
Benzinga
Benzinga
金曜日, 10 23
Benzinga
© 2026 Benzinga | All Rights Reserved
SAB Biotherapeutics (SABS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.28 | $-0.21 | $-0.33 | $-0.51 |
| Actual | $-0.28 | $-0.35 | $-0.46 | $-0.21 |
| Surprise | 0.00% | -66.7% | -39.4% | +58.8% |
| Revenue | ||||
| Estimate | — | — | $249998 | $249998 |
| Actual | $0 | $0 | $0 | $0 |
| Surprise | — | — | -100.0% | -100.0% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.27 | $-0.27 |
| Revenue | ||
| Consensus | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.28 | $-0.28 | 0.00 % |
| Q1 | May 12, 2026 | $-0.35 | $-0.21 | -66.7 % |
| Q4 | Mar 9, 2026 | $-0.46 | $-0.33 | -39.4 % |
| Q3 | Nov 13, 2025 | $-0.21 | $-0.51 | 58.8 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q4 | Mar 9, 2026 | $0 | $250.00K | -100.0 % |
| Q3 | Nov 13, 2025 | $0 | $250.00K | -100.0 % |
| Q2 | Aug 7, 2025 | $0 | $260.00K | -100.0 % |
| Q1 | May 9, 2025 | $0 | $260.00K | -100.0 % |